OncoVista Innovative Therapies(OTC) OVIT

OncoVista Innovative Therapies, Inc. is a drug development company focused on creating targeted cancer therapies. The company specializes in drug discovery, registration strategies, and emerging technologies, with a commitment to advancing cancer treatment options.

Products and Services

• Cordycepin, a potential cancer treatment
• L-Nucleoside Conjugate, targeting specific cancer cells
• Innovative drug discovery and registration strategies

Growth Outlook

• Targeted therapies market projected to grow significantly
• Increased focus on personalized medicine enhances demand
• Strategic partnerships may expand product pipeline

Financial Highlights

• Recent quarterly net income of -$326,098
• Trailing twelve months (TTM) revenue of $0
• Cash and cash equivalents of $61,270 as of September 30, 2015

OncoVista Innovative Therapies, Inc. operates in the medical pharmaceuticals industry, with a focus on developing innovative cancer therapies. The company has produced notable products like Cordycepin and L-Nucleoside Conjugate, which aim to provide targeted treatment options for cancer patients. The growth outlook for OncoVista is promising, as the targeted therapies market is expected to expand significantly, driven by the increasing emphasis on personalized medicine. Additionally, potential strategic partnerships could further enhance the company's product pipeline. Financially, OncoVista has faced challenges, as evidenced by a recent quarterly net income of -$326,098 and a TTM revenue of $0. However, the company maintains a cash position of $61,270, which may support ongoing research and development efforts. Investors may find interest in the company's innovative approach to cancer treatment and its potential for future growth in a rapidly evolving market.